Request Information
Request Information
Aug 07 2017
ZDNet
Auris Health, formerly known as Auris Surgical Robotics, is featured in the article for raising an unprecedented amount of funding in 2017. According to this article, Auris raised $280 million in a Series D round. After raising a large investment, Auris has remained silent about its work on the Monarch Platform, creating great intrigue in the financial media.
Dr. Frederic Moll, a well-known innovator in the surgical robotics field, got FDA approval for the medical robot which featured an endoscope designed to be used in the lungs. However, this system has not been made available commercially. According to this article, 150,000 people every year are killed by cancers in the lung.
Excerpt from article:
"Last year, Auris got FDA approval for its first medical robot, an endoscope to help treat lung conditions. That bot is part of a class of flexible robots that avoid cutting patients by using the body's natural openings--the mouth, in the case of the FDA-cleared bot."
Read the full article about AurisBronchoscopy:
Complications from bronchoscopy are rare and most often minor, but if they occur, may include breathing difficulty, vocal cord spasm, hoarseness, slight fever, vomiting, dizziness, bronchial spasm, infection, low blood oxygen, bleeding from biopsied site, or an allergic reaction to medications. Only rarely do patients experience other more serious complications (for example, collapsed lung, respiratory failure, heart attack and/or cardiac arrhythmia).
Urology:
Adverse effects from both Mini-PCNL and Ureteroscopy include pain, urinary tract infection, fever, hematuria (presence of blood in urine), exposure to low levels of radiation, retained or residual stones.
Adverse effects from ureteroscopy may include pain, perforation or injury to the ureter, resulting in extravasation of fluid and urine (urinoma), stricture of the ureter with risk of subsequent obstruction (hydronephrosis needing further repair), rare avulsion of the ureter, urinary blood clots, residual stones.
PCNL access may result in minor and major adverse effects. Minor effects include fever and nephrostomy leak. Major adverse effects may include injuries to pleura, liver, spleen, large vessels with related bleeding, gallbladder, duodenum, jejunum, colon with related cutaneous fistula, fever, pain, ileus, elevated counts.
Major adverse effects related to stone removal may include infection and urosepsis, intravascular fluid overload, extravasation of fluid, and post percutaneous nephrolithotomy bleeding.